Lymphoma Clinical Trials in Nashville

Showing 341-360 of 654 trials

A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas

NCT02395601

First in human, open-label, sequential dose escalation and expansion study of CPI-1205 in patients with progressive B-cell lymphomas. CPI-1205 is a small molecule inhibitor of EZH2.

B-Cell Lymphoma

Constellation Pharmaceuticals41 participantsStarted Mar 2015

Lafayette, Indiana, United States • Boston, Massachusetts, United States • Omaha, Nebraska, United States +3 more locations

COMPLETEDPhase 1< 1 mile

A Study of LY3023414 in Participants With Advanced Cancer

NCT01655225

The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer. The study will also explore the changes to various markers in blood cells and potentially tumor cells. Finally, the study will help document any antitumor activity this drug may have. In Part A of this study, participants with advanced/metastatic cancer (including lymphoma) will receive increasing doses of LY3023414. In Part B, LY3023414 will be explored in different types of cancer, including breast and lung cancer, lymphoma and mesothelioma.

Advanced CancerMetastatic CancerNon-Hodgkin's Lymphoma+3 more

Eli Lilly and Company156 participantsStarted Jul 2012

Los Angeles, California, United States • New York, New York, United States • Oklahoma City, Oklahoma, United States +5 more locations

A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas

A Study of LY3023414 in Participants With Advanced Cancer

Lymphoma Trials in Other Cities

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Double Cord Versus Haploidentical (BMT CTN 1101)

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia

Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)

Illness Management and Parental Adjustment to Cancer Treatment

Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies

Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma

Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi

Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects

Other Conditions in Nashville